CCND1 and cancer: Downregulation of ARE-BPs is observed in cancers, leading to stabilization of mRNA targets involved in the cell cycle (cyclin D1, for example), in angiogenesis (VEGF, for example), or in apoptotic resistance (BCL2, for example).